Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...

Including 24-hour urine testing in multiple myeloma response assessments is largely unnecessary, a new phase 3 trial suggests ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...